GEODE CAPITAL MANAGEMENT, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 165 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2015. The put-call ratio across all filers is 4.61 and the average weighting 0.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$442,000
-4.5%
2,239,826
+118.1%
0.00%
Q3 2018$463,000
-11.0%
1,027,121
-0.6%
0.00%
Q2 2018$520,000
-80.2%
1,033,790
-8.1%
0.00%
-100.0%
Q1 2018$2,620,000
-16.6%
1,124,654
+1.7%
0.00%0.0%
Q4 2017$3,140,000
+14.7%
1,105,741
+15.5%
0.00%0.0%
Q3 2017$2,738,000
+17.7%
957,664
+1.7%
0.00%0.0%
Q2 2017$2,326,000
-27.1%
941,824
+6.6%
0.00%0.0%
Q1 2017$3,190,000
+14.7%
883,786
+12.5%
0.00%0.0%
Q4 2016$2,781,000
-9.7%
785,672
+3.0%
0.00%
-50.0%
Q3 2016$3,080,000
+4.1%
762,569
+13.1%
0.00%0.0%
Q2 2016$2,959,000
+16.9%
674,181
+0.7%
0.00%
+100.0%
Q1 2016$2,531,000
-75.5%
669,587
+1.7%
0.00%
-83.3%
Q4 2015$10,326,000
+54.0%
658,605
+3.5%
0.01%
+50.0%
Q3 2015$6,705,000
-58.4%
636,205
-0.6%
0.00%
-55.6%
Q2 2015$16,135,000
-4.7%
639,806
+5.3%
0.01%
-10.0%
Q1 2015$16,936,000
+77.7%
607,692
+16.3%
0.01%
+66.7%
Q4 2014$9,532,000
+44.6%
522,350
+2.7%
0.01%
+50.0%
Q3 2014$6,593,000
-20.5%
508,763
+0.1%
0.00%
-20.0%
Q2 2014$8,293,000
-7.2%
508,173
+0.5%
0.01%
-16.7%
Q1 2014$8,937,000
-19.3%
505,798
+10.6%
0.01%
-25.0%
Q4 2013$11,071,000
-25.0%
457,314
+9.7%
0.01%
-33.3%
Q3 2013$14,765,000
+180.3%
416,742
+23.5%
0.01%
+140.0%
Q2 2013$5,268,000337,4650.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2015
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders